InvestSMART

Oncosil Medical Limited (ASX: OSL) - Announcements

Current share price for OSL : $1.275 0.07 (5.20%)+

ASX company news and announcements for Oncosil Medical Limited (OSL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Oncosil Medical Limited (OSL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Oncosil Medical Limited (OSL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Oncosil Medical Limited (OSL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$39 OSL announces $8.7m capital raise to drive commercialisation 26 May 2025 10:17AM $0.004 $1.275 risen by 36,328.57%
$39 Trading Halt 22 May 2025 8:34AM $0.004 $1.275 risen by 36,328.57%
$39 OncoSil Outperforms SBRT in Pancreatic Cancer Outcomes 7 May 2025 8:33AM $0.004 $1.275 risen by 31,775%
$39 Application for quotation of securities - OSL 5 May 2025 4:45PM $0.003 $1.275 risen by 42,400%
$39 Quarterly Activities/Appendix 4C Cash Flow Report Addendum 2 May 2025 5:25PM $0.004 $1.275 risen by 36,328.57%
$39 Update - Consolidation/Split - OSL 1 May 2025 5:05PM $0.004 $1.275 risen by 36,328.57%
$39 Consolidation/Split - OSL 1 May 2025 12:23PM $0.004 $1.275 risen by 31,775%
$39 Tender Process for CRO to Undertake G-BA Study Commences 30 Apr 2025 3:29PM $0.004 $1.275 risen by 31,775%
$39 Notice of Extraordinary General Meeting/Proxy Form 30 Apr 2025 10:15AM $0.005 $1.275 risen by 25,400%
$39 Quarterly Activities/Appendix 4C Cash Flow Report 29 Apr 2025 2:27PM $0.005 $1.275 risen by 25,400%
$39 Appointment of Company Secretary 1 Apr 2025 8:20AM $0.005 $1.275 risen by 28,233.33%
$39 OncoSil appoints Ms Shelley Steyn as Chief Financial Officer 18 Mar 2025 8:30AM $0.005 $1.275 risen by 25,400%
$39 Appendix 4D and Half Year Accounts 25 Feb 2025 4:59PM $0.006 $1.275 risen by 21,150%
$39 Investor Webinar Presentation 11 Feb 2025 2:34PM $0.006 $1.275 risen by 21,150%
$39 Investor Webinar 11 February 2025 7 Feb 2025 12:28PM $0.007 $1.275 risen by 18,114.29%
$39 120 German Hospitals entitled to negotiate fee for OncoSil 4 Feb 2025 8:37AM $0.005 $1.275 risen by 25,400%
$39 Response to Appendix 3X Query 31 Jan 2025 6:21PM $0.006 $1.275 risen by 21,150%
$39 Quarterly Activities/Appendix 4C Cash Flow Report 30 Jan 2025 8:48AM $0.006 $1.275 risen by 21,150%
$39 Initial Director's Interest Notice LS 29 Jan 2025 10:32AM $0.006 $1.275 risen by 21,150%
$39 OncoSil Medical Receives MDR Approval 28 Jan 2025 9:57AM $0.005 $1.275 risen by 25,400%
$39 Lel Smits to be appointed Non-Executive Director 15 Jan 2025 9:52AM $0.005 $1.275 risen by 25,400%
$39 OncoSil receives $1.05m R&D tax incentive 8 Jan 2025 2:47PM $0.006 $1.275 risen by 23,081.82%
$39 First Patient in Australia Randomised in TRIPP-FFX Trial 31 Dec 2024 10:05AM $0.006 $1.275 risen by 21,150%
$39 Change of Director's Interest Notice DC 20 Dec 2024 9:20AM $0.006 $1.275 risen by 21,150%
$39 Notification regarding unquoted securities - OSL 13 Dec 2024 1:32PM $0.007 $1.275 risen by 18,114.29%

151 - 175 of 791 results

Page 7 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.